Abstract:Objective: To compare the pharmacokinetic properties of two newly developed generic ambroxol formulations with a branded innovator product in healthy Chinese male volunteers. Methods: This was a single-dose, randomized, open-label, three-period crossover study in healthy volunteers aged 18 45 years under fasting conditions. Subjects were assigned to receive 1 of 2 test formulations or a reference tablet of ambroxol 30 mg. Each study period was separated by a 1-week washout phase. Blood samples were collected at pre-specified times. A non-compartmental method was employed to determine pharmacokinetic properties (C-max, t(max), AUC(0-tlast), AUC(0-infinity)) to test for bioequivalence. The predetermined regulatory range of 90% CI for bioequivalence was 80 -125%. Results: 24 subjects were enrolled in and completed the study. The geometric mean Cmax values for the test tablet, test capsule, and reference product were 82.73, 85.36, 84.56 ng/mL, and their geometric mean AUC(0-tlast), (AUC(0-infinity)) were 660.87 (753.49), 678.98 (756.79), and 639.41 (712.14) ng x h/mL, respectively. For test tablet vs. reference, the 90% CIs of the least squares mean test/reference ratios of C-max, AUC(0-tlast) and AUC(0-infinity) were 91.2% to 104.9%, 96.5% to 110.7%, and 98.8% to 113.4%, respectively. For test capsule, the corresponding values were 94.1% to 108.3%, 99.2% to 113.7%, and 99.2% to 113.9%, respectively. No adverse events occurred during the study. Conclusions: The ambroxol 30 mg tablets and capsules were considered bioequivalent to the reference formulation in accordance with predetermined regulatory criteria.

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Bioequivalence of Azithromycin Tablets in Healthy Volunteers

Pharmacokinetics and relative bioavailability of domestic vs imported cefpodoxime proxetil tablets in human body

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Bioequivalence of erythromycin enteric-coated capsules in healthy volunteers

Bioequivalence Evaluation of Two Rabeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

Pharmacokinetics and Bioequivalence Studies of Roxatidine Acetate Hydrochloride Sustained‐Release Capsule in Healthy Chinese Subjects

Bioequivalence of Domestic Azithromycin Granules in Healthy Volunteers

Relative bioavailability of cefpodoxime proxetil tablets in healthy volunteers

Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Pharmacokinetic And Bioequivalence Study Of Three Oral Formulations Of Ambroxol 30 Mg: A Randomized, Three-Period Crossover Comparison In Healthy Volunteers

Bioequivalence of Pantoprazole Sodium Enteric-Coated Capsules in Human

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

Evaluation of quality consistency of enteric-coated capsule azithromycin with imported tablet of azithromycin

Pharmacokinetics and Bioequivalence of Two Formulations of Rosuvastatin Following Single‐dose Administration in Healthy Chinese Subjects Under Fasted and Fed Conditions

Bioequivalence study of fluoxetine capsules in healthy volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioequivalence of Lansoprazole Enteric Caspsules in Healthy Volunteers

Study on Bioequivalence of Ambroxol Hydrochloride Tablets from Domestic and Import